Clinical rheumatology · 2025
Global burden of rheumatic vs non-rheumatic valvular heart disease, 1990-2021: a systematic analysis of the global burden of disease study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tang Huirui, Zhang Kexin, Chen Jinyan, Zhang Xiaofei, Yu Xiao, Ren Jiayi, Wang Yuqun, Ma Yujie, Hou Ningning, Kan Chengxia, Sun Xiaodong
Аннотация
OBJECTIVES: This study aims to systematically analyze global, regional, and national trends in the incidence, mortality, and disability-adjusted life years (DALYs) of rheumatic heart disease (RHD) and non-rheumatic valvular heart disease (NRVHD) from 1990 to 2021, and to project future trends through 2036 using data from the Global Burden of Disease Study 2021.
METHODS: Data were extracted from the Global Health Data Exchange and stratified by age, sex, and socio-demographic index (SDI). The analysis included cases, deaths, mortality rates, DALYs, and age-standardized rates (ASIR, ASMR, and ASDR) for both RHD and NRVHD. Projections for 2022-2036 were made using the ARIMA model.
RESULTS: In 2021, the global incidence of RHD was estimated at 3.85 million cases (95% UI: 3,056,084.82-4,783,797.73), with a higher prevalence among females (53.41%). RHD accounted for 373,345 deaths (95% UI: 324,139.65-444,761.76), with females comprising 56.98% of these. DALYs due to RHD totaled 13.43 million (95% UI: 11,517,020.93-15,780,163.69), with females representing 55.05%. The incidence of NRVHD reached 2.21 million cases (95% UI: 2,048,266.87-2,375,325.37), predominantly among males (60.17%). However, NRVHD-related deaths totaled 181,078 (95% UI: 155,363.66-195,716.85), with females accounting for a higher proportion (58.79%). DALYs due to NRVHD reached 3.24 million (95% UI: 2,934,104.15-3,594,473.74). From 1990 to 2021, RHD mortality declined in high-income countries but remained a major cause of death in low- and middle-income countries. In contrast, both the incidence and mortality of NRVHD increased significantly, particularly in high-income countries, driven by aging populations and lifestyle-related risk factors.
CONCLUSION: This study underscores the substantial global burden of RHD and NRVHD. RHD disproportionately affects younger populations in low- and middle-income countries, while NRVHD is increasingly prevalent among older adults in high-income countries. Early diagnosis and timely intervention are essential to mitigating the worldwide impact of these conditions. Key Points • Systematically analyzes global trends of RHD and NRVHD from 1990 to 2021 and projected to 2036. • RHD remains prevalent in younger populations in low- and middle-income countries. • NRVHD is rising among older adults in high-income regions.
METHODS: Data were extracted from the Global Health Data Exchange and stratified by age, sex, and socio-demographic index (SDI). The analysis included cases, deaths, mortality rates, DALYs, and age-standardized rates (ASIR, ASMR, and ASDR) for both RHD and NRVHD. Projections for 2022-2036 were made using the ARIMA model.
RESULTS: In 2021, the global incidence of RHD was estimated at 3.85 million cases (95% UI: 3,056,084.82-4,783,797.73), with a higher prevalence among females (53.41%). RHD accounted for 373,345 deaths (95% UI: 324,139.65-444,761.76), with females comprising 56.98% of these. DALYs due to RHD totaled 13.43 million (95% UI: 11,517,020.93-15,780,163.69), with females representing 55.05%. The incidence of NRVHD reached 2.21 million cases (95% UI: 2,048,266.87-2,375,325.37), predominantly among males (60.17%). However, NRVHD-related deaths totaled 181,078 (95% UI: 155,363.66-195,716.85), with females accounting for a higher proportion (58.79%). DALYs due to NRVHD reached 3.24 million (95% UI: 2,934,104.15-3,594,473.74). From 1990 to 2021, RHD mortality declined in high-income countries but remained a major cause of death in low- and middle-income countries. In contrast, both the incidence and mortality of NRVHD increased significantly, particularly in high-income countries, driven by aging populations and lifestyle-related risk factors.
CONCLUSION: This study underscores the substantial global burden of RHD and NRVHD. RHD disproportionately affects younger populations in low- and middle-income countries, while NRVHD is increasingly prevalent among older adults in high-income countries. Early diagnosis and timely intervention are essential to mitigating the worldwide impact of these conditions. Key Points • Systematically analyzes global trends of RHD and NRVHD from 1990 to 2021 and projected to 2036. • RHD remains prevalent in younger populations in low- and middle-income countries. • NRVHD is rising among older adults in high-income regions.